Company Description
Merck & Co., Inc. operates as a healthcare company worldwide.
It operates through two segments, Pharmaceutical and Animal Health.
The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.
The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products.
It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers.
The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV.
Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Country | United States |
IPO Date | Jan 13, 1978 |
Industry | Drug Manufacturers - General |
Sector | Healthcare |
Employees | 70,000 |
CEO | Robert M. Davis J.D. |
Contact Details
Address: 2000 Galloping Hill Road Kenilworth, New Jersey United States | |
Website | https://www.merck.com |
Stock Details
Ticker Symbol | MRK |
Exchange | NYSE |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0000310158 |
CUSIP Number | 58933Y105 |
ISIN Number | US58933Y1055 |
Employer ID | 22-1918501 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Robert M. Davis J.D. | Chairman, President & Chief Executive Officer |
Caroline Litchfield | Executive Vice President & Chief Financial Officer |
Cristal N. Downing | Executive Vice President and Chief Communications & Public Affairs Officer |
Dalton E. Smart III | Senior Vice President of Finance, Principal Accounting Officer & Global Controller |
David Michael Williams | Executive Vice President and Chief Information & Digital Officer |
Dr. Dean Y. Li M.D., Ph.D. | Executive Vice President & President of Merck Research Laboratories |
Jennifer L. Zachary J.D. | Executive Vice President & General Counsel |
Peter Dannenbaum | Vice President of Investor Relations |
Richard R. DeLuca Jr. | Executive Vice President & President of Merck Animal Health |
Sanat Chattopadhyay | Executive Vice President & President of Merck Manufacturing Division |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Nov 22, 2024 | 8-K | Current Report |
Nov 06, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Nov 06, 2024 | 10-Q | Quarterly Report |
Nov 04, 2024 | 25-NSE | Filing |
Oct 31, 2024 | 8-K | Current Report |
Oct 01, 2024 | 4 | Filing |
Oct 01, 2024 | 4 | Filing |
Oct 01, 2024 | 4 | Filing |
Aug 06, 2024 | 4 | Filing |
Aug 05, 2024 | 10-Q | Quarterly Report |